Abstract
At the request of the corresponding author, the JCI is retracting this article. Following an institutional investigative review of errors in the article, it was determined that the data reported in Figure 1B were an analysis of E2F1 expression rather than CERS6 expression, as originally reported. The correct data do not show a difference in CERS6 expression with invasion status in human lung adenocarcinomas. In addition, errors were noted in Supplemental Figure 2, Supplemental Figure 3B, and Supplemental Table 1. The institutional review found no evidence of intention to falsify results.
| Original language | English |
|---|---|
| Pages (from-to) | 5050 |
| Number of pages | 1 |
| Journal | Journal of Clinical Investigation |
| Volume | 129 |
| Issue number | 11 |
| DOIs |
|
| Publication status | Published - 01-11-2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- General Medicine
Fingerprint
Dive into the research topics of 'Erratum: Targeting ceramide synthase 6–dependent metastasis-prone phenotype in lung cancer cells(Journal of Clinical Investigation(2016)126: (1()254–265)Doi:10.1172/JCI79775)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver